Ajanta Pharma Shares Gain 5% After Semaglutide Deal With Biocon

December 24, 2025December 24, 2025

Shares of Ajanta Pharma Ltd. surged 5% to touch a day’s high of Rs 2,824 on 24th December. This occurred after the company said it had inked an in-licensing agreement with Biocon Ltd. for semaglutide, a GLP-1 receptor agonist.

Under the agreement, Biocon will supply semaglutide to Ajanta Pharma for exclusive marketing in 23 countries. Additionally, there will be semi-exclusive marketing in three countries across Africa, Central Asia, and the Middle East.

Semaglutide is used to improve glycaemic control in adults. The product patent is set to expire in most of these markets in March 2026. Ajanta Pharma plans to commercialise the drug after receiving the necessary regulatory approvals. These approvals are expected in late 2026 or early 2027.

Commenting on the development, Managing Director Yogesh Agarwal said that GLP-1 therapies have seen rapid global adoption and emerged as blockbuster products. He added that Ajanta Pharma is excited to partner with Biocon on semaglutide. They plan to bring this important therapy to markets where the company has a strong on-the-ground presence and deep distribution reach.

At 12:16 PM, shares of Ajanta Pharma were trading 3.03% higher at Rs 2,749 on NSE.

Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!